Stoke Therapeutics, Inc.
STOK
$33.61
$0.631.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 205.63M | 199.89M | 190.91M | 36.56M | 16.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 205.63M | 199.89M | 190.91M | 36.56M | 16.74M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 205.63M | 199.89M | 190.91M | 36.56M | 16.74M |
| SG&A Expenses | 58.79M | 55.45M | 53.23M | 48.79M | 46.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 178.44M | 159.61M | 152.67M | 137.93M | 134.05M |
| Operating Income | 27.20M | 40.28M | 38.24M | -101.37M | -117.30M |
| Income Before Tax | 40.57M | 53.76M | 51.55M | -88.98M | -105.46M |
| Income Tax Expenses | 0.00 | 1.28M | 1.28M | -- | -- |
| Earnings from Continuing Operations | 40.57 | 52.48 | 50.27 | -88.98 | -105.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.57M | 52.48M | 50.27M | -88.98M | -105.46M |
| EBIT | 27.20M | 40.28M | 38.24M | -101.37M | -117.30M |
| EBITDA | 29.09M | 42.27M | 40.33M | -99.19M | -115.03M |
| EPS Basic | 0.71 | 0.90 | 0.84 | -1.68 | -2.10 |
| Normalized Basic EPS | 0.44 | 0.57 | 0.54 | -1.05 | -1.31 |
| EPS Diluted | 0.66 | 0.84 | 0.79 | -1.68 | -2.10 |
| Normalized Diluted EPS | 0.41 | 0.54 | 0.51 | -1.05 | -1.31 |
| Average Basic Shares Outstanding | 231.86M | 229.59M | 227.00M | 215.38M | 203.31M |
| Average Diluted Shares Outstanding | 233.39M | 231.12M | 228.53M | 215.38M | 203.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |